fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Misoprostol

All products: general benefit

Misoprostol · DIN 02244022 · 100 mcg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
Misoprostol · DIN 02244022 Manufacturer: A A Pharma Inc.; listing date 2002-04-04 Health Canada: Marketed since 2011-12-14 · brand MISOPROSTOL · ATC A02BB01 MISOPROSTOL · form Tablet · route Oral · ingredients MISOPROSTOL 100 MCG · company Aa pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Misoprostol: Formulary list price $0.26 per unit (the source does not state the unit; exact figure $0.2636). What the ministry pays, not the patient.

Ministry pays: $0.2636 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02244022)

Source record
DIN 02244022: Misoprostol Raw flags: chronicUseMed=Y, sec3=Y Item: 564000029; group id 685; item number 1704; lccId None; manufacturer id AAP Source form: Tab; strength: 100mcg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2636; ministry $0.2636 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02244022 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67965
Interchangeable products
Cytotec · DIN 00813966 · not recorded
Shortage status: resolved shortage (ended May 12, 2023); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02244022
Shortage record checked October 6, 2026

Other products in the same Health Canada class (A02B): coverage varies; not interchangeable

  • Cimetidine: general benefit, not a benefit
  • Famotidine (Pepcid): general benefit, not a benefit
  • Nizatidine (Axid): general benefit
  • Pantoprazole (Tecta): general benefit
  • Rabeprazole (Pariet): general benefit
  • Ranitidine (Zantac): general benefit, not a benefit

7 more in the class list below

Other drugs in the same formulary class (56:40 Miscellaneous G.I. Drugs) and how they are covered

Matched class: 56:40 Miscellaneous G.I. Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BUDESONIDE, MESALAZINE, NIZATIDINE, OLSALAZINE SODIUM, PANTOPRAZOLE MAGNESIUM, RABEPRAZOLE SODIUM, SUCRALFATE Some products covered without a code (check the product listing): 5-AMINOSALICYLIC ACID, CIMETIDINE, DOMPERIDONE MALEATE, FAMOTIDINE, LACTULOSE, METOCLOPRAMIDE HCL, RANITIDINE HCL 56:40 Miscellaneous G.I. Drugs

CIMETIDINE

· 10 products · General benefit (5), Listed, not a benefit (5) · strengths: 200mg, 300mg, 400mg, 600mg, 800mg · Tab

FAMOTIDINE

· 16 products · Listed, not a benefit (2), General benefit (14) · strengths: 20mg, 40mg · Tab

NIZATIDINE

· 2 products · General benefit · strengths: 150mg, 300mg · Cap

PANTOPRAZOLE MAGNESIUM

· 6 products · General benefit · strengths: 40mg · Ent Coated Tab

RABEPRAZOLE SODIUM

· 16 products · General benefit · strengths: 10mg, 20mg · Tab

RANITIDINE HCL

· 23 products · Listed, not a benefit (3), General benefit (20) · strengths: 15mg/mL, 150mg, 300mg · Oral Sol, Tab

SUCRALFATE

· 4 products · General benefit · strengths: 1g/5mL, 1g · Oral Susp, Tab

LANSOPRAZOLE

· 16 products · Limited Use, codes 293, 295, 297, 401, 402 · strengths: 15mg, 30mg · DR Cap

LANSOPRAZOLE & CLARITHROMYCIN & AMOXICILLIN

· 2 products · Listed, not a benefit (1), Limited Use, codes 306, 307 (1) · strengths: 30mg & 500mg & 500mg · Tab/Cap Pk

OMEPRAZOLE

· 19 products · Off-Formulary Interchangeable, not an ODB benefit (4), Listed, not a benefit (2), Limited Use, codes 293, 297, 401, 402 (13) · strengths: 10mg, 20mg · DR Cap

PANTOPRAZOLE SODIUM

· 30 products · Off-Formulary Interchangeable, not an ODB benefit (10), Limited Use, codes 293, 295, 297, 401, 402 (20) · strengths: 20mg, 40mg · Ent Tab

DEXLANSOPRAZOLE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 30mg, 60mg · DR Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 56:40 and 10 more
Full class listing Related classes: 56:04 Antacids and Adsorbents, 56:08 Antidiarrhea Agents, 56:12 Cathartics, 56:16 Digestants, 56:22 Antiemetics and Antinauseants Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE MISOPROSTOL (misoprostol) is indicated for the treatment and prevention of NSAID-induced gastroduodenal ulcers. MISOPROSTOL is also indicated for the treatment of duodenal ulcers caused by Peptic Ulcer Disease (PUD). 4 Patients at high risk of developing NSAID-induced complications and who may require protection include: – Patients with a previous history of ulcer disease or a significant gastrointestinal event. – Patients over 60 years of age. – Patient judged to be at risk because of general poor health, severe concomitant medical disease, or patients who are poor surgical risks. – Patients disabled by joint symptoms (e.g. HAQ Disability Index Score > 1.5) or those with severe systemic manifestations of arthritis. – Patients taking other drugs known to damage or exacerbate damage to the gastrointestinal tract such as corticosteroids or anticoagulants. – Patients taking a high dosage or multiple NSAIDs, including those available Over-The- Counter. The risk of NSAID-induced complications may be highest in the first three months of NSAID… https://pdf.hres.ca/dpd_pm/00010610.PDF PM date: not printed or not captured Source product: MISOPROSTOL; DIN 02244022; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.